Tags

Type your tag names separated by a space and hit enter

Continuous subcutaneous insulin infusion leads to immediate, stable and long-term changes in metabolic control.
Diabetes Obes Metab. 2008 Apr; 10(4):329-35.DO

Abstract

BACKGROUND

Evaluations of continuous subcutaneous insulin infusion (CSII) usually focus on one pre- and one post-CSII measurement to assess metabolic therapy outcome.

AIM

Extending this research, the aim of the present study was to provide a more fine-grained analysis of achieved glycaemic control.

METHODS

In 52 patients with type 1 diabetes (mean age of 37.85 years at CSII begin; s.d. +/- 12.41), haemoglobin A(1c) (HbA(1c)) levels were assessed every 3 months over a period of 5 years (1 year before and 4 years after the introduction of CSII). Mixed models were utilized to describe changes in glycaemic control.

RESULTS

The pre-post course showed that already in the first quarter, a statistically significant lower HbA(1c) level was obtained [7.30%, in contrast to 8.21% at the last quarter with intensified conventional therapy (ICT)]. In the following 15 quarters, the mean HbA(1c) levels remained constantly lower than that with ICT. Overall, the aggregated mean HbA(1c) level of patients with CSII therapy was 7.19%, in contrast to 8.08% with ICT; thus, an overall decrease by 11% was achieved. In addition, individual differences in blood glucose level and age of diabetes onset as a predictor for therapy success were analysed.

CONCLUSIONS

The data show an immediate, stable and long-term effect of CSII on HbA(1c). In addition, a significant relationship between metabolic control and age of diabetes onset was found, as well as a reduction of variance in HbA(1c) levels between subjects after change to CSII.

Authors+Show Affiliations

Department of Psychology, University of Zurich, Zurich, Switzerland.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18333891

Citation

Aberle, I, et al. "Continuous Subcutaneous Insulin Infusion Leads to Immediate, Stable and Long-term Changes in Metabolic Control." Diabetes, Obesity & Metabolism, vol. 10, no. 4, 2008, pp. 329-35.
Aberle I, Zimprich D, Bach-Kliegel B, et al. Continuous subcutaneous insulin infusion leads to immediate, stable and long-term changes in metabolic control. Diabetes Obes Metab. 2008;10(4):329-35.
Aberle, I., Zimprich, D., Bach-Kliegel, B., Fischer, C., Gorny, M., Kliegel, A., Langer, K., & Kliegel, M. (2008). Continuous subcutaneous insulin infusion leads to immediate, stable and long-term changes in metabolic control. Diabetes, Obesity & Metabolism, 10(4), 329-35. https://doi.org/10.1111/j.1463-1326.2007.00707.x
Aberle I, et al. Continuous Subcutaneous Insulin Infusion Leads to Immediate, Stable and Long-term Changes in Metabolic Control. Diabetes Obes Metab. 2008;10(4):329-35. PubMed PMID: 18333891.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Continuous subcutaneous insulin infusion leads to immediate, stable and long-term changes in metabolic control. AU - Aberle,I, AU - Zimprich,D, AU - Bach-Kliegel,B, AU - Fischer,C, AU - Gorny,M, AU - Kliegel,A, AU - Langer,K, AU - Kliegel,M, PY - 2008/3/13/pubmed PY - 2008/7/29/medline PY - 2008/3/13/entrez SP - 329 EP - 35 JF - Diabetes, obesity & metabolism JO - Diabetes Obes Metab VL - 10 IS - 4 N2 - BACKGROUND: Evaluations of continuous subcutaneous insulin infusion (CSII) usually focus on one pre- and one post-CSII measurement to assess metabolic therapy outcome. AIM: Extending this research, the aim of the present study was to provide a more fine-grained analysis of achieved glycaemic control. METHODS: In 52 patients with type 1 diabetes (mean age of 37.85 years at CSII begin; s.d. +/- 12.41), haemoglobin A(1c) (HbA(1c)) levels were assessed every 3 months over a period of 5 years (1 year before and 4 years after the introduction of CSII). Mixed models were utilized to describe changes in glycaemic control. RESULTS: The pre-post course showed that already in the first quarter, a statistically significant lower HbA(1c) level was obtained [7.30%, in contrast to 8.21% at the last quarter with intensified conventional therapy (ICT)]. In the following 15 quarters, the mean HbA(1c) levels remained constantly lower than that with ICT. Overall, the aggregated mean HbA(1c) level of patients with CSII therapy was 7.19%, in contrast to 8.08% with ICT; thus, an overall decrease by 11% was achieved. In addition, individual differences in blood glucose level and age of diabetes onset as a predictor for therapy success were analysed. CONCLUSIONS: The data show an immediate, stable and long-term effect of CSII on HbA(1c). In addition, a significant relationship between metabolic control and age of diabetes onset was found, as well as a reduction of variance in HbA(1c) levels between subjects after change to CSII. SN - 1463-1326 UR - https://www.unboundmedicine.com/medline/citation/18333891/Continuous_subcutaneous_insulin_infusion_leads_to_immediate_stable_and_long_term_changes_in_metabolic_control_ L2 - https://doi.org/10.1111/j.1463-1326.2007.00707.x DB - PRIME DP - Unbound Medicine ER -